Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration

Background: Laser treatment of extrafoveal well delineated choroidal neovascularisation in exudative age related macular degeneration has a high rate of failure with subsequent severe vision loss from subfoveal involvement. Laser treatment may limit scotoma size, but is unpalatable because of early...

Full description

Saved in:
Bibliographic Details
Published in:British journal of ophthalmology 2002-05, Vol.86 (5), p.527-529
Main Authors: Ranson, N T, Danis, R P, Ciulla, T A, Pratt, L
Format: Article
Language:English
Subjects:
Anti-Inflammatory Agents - administration & dosage
Biological and medical sciences
Care and treatment
Cataracts
Choroidal Neovascularization - drug therapy
Choroidal Neovascularization - surgery
Dosage and administration
Drug therapy
Eye
Humans
Laser Coagulation - methods
laser photocoagulation
Lasers
Macular degeneration
Macular Degeneration - surgery
Medical imaging
Medical sciences
neovascularisation
Neovascularization
Patients
Pharmacology. Drug treatments
Recurrence
Retinal degeneration
Scientific Correspondence
Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases
Surgery of the eye and orbit
Triamcinolone
Triamcinolone - administration & dosage
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Laser treatment of extrafoveal well delineated choroidal neovascularisation in exudative age related macular degeneration has a high rate of failure with subsequent severe vision loss from subfoveal involvement. Laser treatment may limit scotoma size, but is unpalatable because of early persistent vision loss. Intravitreal triamacinolone injection may be an acceptable alternative therapy in such disparate cases. Methods: 14 consecutive patients with recurrent neovascularisation were treated with a single 4.0 mg injection of triamacinolone and followed for up to 1 year. Visual results were compared with published data from the Macular Photocoagulation Study of recurrent neovascularisation. Results: Mean visual acuity remained stable at about 20/200 throughout the study period in the treated patients. This is comparable to the outcomes in the Macular Photocoagulation Study for laser retreated patients, and better than the observation group. Conclusions: Intravitreal triamcinolone may be an acceptable treatment of subfoveal recurrent neovascularisation while avoiding early persistent vision loss from laser retreatment.
ISSN:0007-1161
1468-2079
DOI:10.1136/bjo.86.5.527